CClinicalTrials.gg
Sign In
Status unknownNCT05177666Updated Jan 4, 2022

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

An observational study in Feasibility, Effectiveness and Safety, sponsored by The University of Hong Kong-Shenzhen Hospital. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-04.

Sponsored by The University of Hong Kong-Shenzhen Hospital · Observational

The sponsor has not verified this record recently (last verified Dec 2021), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective registration study for patients with advanced refractory solid tumors. Patients who meet the eligibility criteria will be included to participate in the study, and baseline information to be collected after signed informed consent. Patients will choose for themselves whether to carry out targeted therapy or other appropriate treatment methods. And we plan to follow up for at least 12 months or until disease progression or death.

Read the detailed description
  1. Screen and enroll 120 patients with refractory solid tumors, and sign informed consents;
  2. Extract the clinical data, including gender, age, disease diagnosis, past treatment history and genetic test results, etc.;
  3. Take biopsy samples and perform NGS testing on patients. After discussion by the Molecular Steering Committee (MTB), the recommendations for treatment guidance will be given based on treatment guidelines and clinical experience;
  4. The patient and the clinician jointly select the treatment plan and follow-up until the patient's disease progresses. The follow-up time will be 1 year;
  5. During the follow-up period, clinical treatment and routine examination information of patients will be collected;
  6. If the patient fails to receive molecular targeted therapy or they cannot tolerate the adverse reaction of the drug after adequate treatment, the clinician will evaluate whether a second NGS resistance test is needed or the participant may withdraw from the study.
02

Conditions studied

  • Feasibility
  • Effectiveness
  • Safety
  • Targeted Molecular Therapy
03

In context

Lead sponsor

The University of Hong Kong-Shenzhen Hospital is the lead sponsor of 16 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

From November 2021 to November 2022, the patients with refractory tumors who underwet the standard treatment standard treatment, went to the Shenzhen Hospital of the University of Hong Kong and were willing to have genetic testing for individualized targeted therapy. It is planned to enroll 120 patients.

Inclusion criteria

  • Recurrent or metastatic malignant solid tumor confirmed by histology or cytology
  • Disease progression or intolerance after receiving standard treatment
  • With evaluable lesions (RECIST 1.1 standard)
  • Tumor tissue pieces with sufficient formalin-fixed paraffin-embedded (FFPE) can be used for genetic testing
  • ECOG PS score 0-4 (3-4 points only for patients with tumor burden)
  • Sign the informed consent form

Exclusion criteria

Exclusion Criteria:

  • The subject is participating in any other clinical research;
  • Researchers believe that serious or uncontrolled medical diseases (ie uncontrolled diabetes, chronic kidney disease, chronic lung disease, or uncontrolled active infections, mental illnesses/social conditions that restrict compliance with research requirements) that will confuse the analysis of research treatment response ；
  • Patients during pregnancy or lactation
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • DrugTargeted therapy

    Based on next-generation sequencing (NGS) detection, after discussion by the Molecular Steering Committee (MTB), intervention guidance suggestions are given based on domestic and foreign guidelines and clinical experience, and finally the patient and clinician jointly choose the treatment plan.

    Also known as: Entratinib, Cabotinib, Aletinib, Enmetrastuzumab, Trastuzumab, Pertuzumab, Vemurafenib, Atilizumab, Bevacizumab, Erlotizumab

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is judged based on RECIST 1.1 criteria for all treatment groups at each visit period.

    Time frame: 2021.11-2023.11

  2. Proportion of targeted therapy guided by tumor molecular characteristics

    The proportion of all enrolled patients receiving targeted therapy guided by tumor molecular characteristics during the study period, would be calculated, which defined as having received one or more the treatments based on tumor molecular characteristics.

    Time frame: 2021.11-2023.11

Secondary outcomes

  1. Progression-free survival (PFS)

    PFS is defined as the time from the first administration to disease progression or death.

    Time frame: 2021.11-2023.11

  2. Overall survival (OS)

    OS is defined as the time from the first administration to death from any cause.

    Time frame: 2021.11-2023.11

  3. Best overall response (BOR)

    The effectiveness of a patient would be evaluated multiple times, and the best one is defined as the best overall response.

    Time frame: 2021.11-2023.11

  4. Adverse events

    The incidence of serious adverse events in each group, which is judged based on CTCAE v5.0 standard.

    Time frame: 2021.11-2023.11

  5. Quality of Life Score (QoL)

    The QoL is evaluated by the scale (0PROMIS-29 Profile v2.1) at each visit period for all the enrolled patients.

    Time frame: 2021.11-2023.11

  6. Proportion of patients with intervening genomic variants

    The intervening genomic variants are defined by the conclusion after MTB discussion.

    Time frame: 2021.11-2023.11

Other outcomes

  1. Changes in ECOG score before and after treatment

    We compare the ECOG scores of each visit with the baseline, including the number and proportion, and the difference.

    Time frame: 2021.11-2023.11

  2. Proportion of targeted therapy guided by second tumor molecular characteristics

    After targeted therapy drug resistance, then the proportion of targeted therapy guided by the second tumor molecular characteristics would be calculated during study period.

    Time frame: 2021.11-2023.11

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012 Mar 8;366(10):883-892. doi: 10.1056/NEJMoa1113205. Erratum In: N Engl J Med. 2012 Sep 6;367(10):976. PubMed 22397650 ↗
  • Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MDM, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van't Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA; Cancer Genome Atlas Research Network; Benz CC, Perou CM, Stuart JM. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014 Aug 14;158(4):929-944. doi: 10.1016/j.cell.2014.06.049. Epub 2014 Aug 7. PubMed 25109877 ↗
  • Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013 Oct;45(10):1127-33. doi: 10.1038/ng.2762. PubMed 24071851 ↗
  • Wheler J, Lee JJ, Kurzrock R. Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. Cancer Res. 2014 Dec 15;74(24):7181-4. doi: 10.1158/0008-5472.CAN-14-2329. Epub 2014 Oct 17. PubMed 25326492 ↗
  • Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, Fitch TR, Wasserman E, Fernandez C, Green S, Sutherland W, Bittner M, Alarcon A, Mallery D, Penny R. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010 Nov 20;28(33):4877-83. doi: 10.1200/JCO.2009.26.5983. Epub 2010 Oct 4. PubMed 20921468 ↗
  • Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012 Nov 15;18(22):6373-83. doi: 10.1158/1078-0432.CCR-12-1627. Epub 2012 Sep 10. PubMed 22966018 ↗
  • Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther. 2016 Apr;15(4):743-52. doi: 10.1158/1535-7163.MCT-15-0795. Epub 2016 Feb 12. PubMed 26873727 ↗
  • Le Tourneau C, Delord JP, Goncalves A, Gavoille C, Dubot C, Isambert N, Campone M, Tredan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bieche I, Bernard V, Gentien D, Jezequel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal M, Paoletti X; SHIVA investigators. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3. PubMed 26342236 ↗
  • Abrahams E, Eck SL. Molecular medicine: Precision oncology is not an illusion. Nature. 2016 Nov 17;539(7629):357. doi: 10.1038/539357e. No abstract available. PubMed 27853199 ↗
  • Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bieche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, Andre F. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020 Nov;31(11):1491-1505. doi: 10.1016/j.annonc.2020.07.014. Epub 2020 Aug 24. PubMed 32853681 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05177666
Lead sponsor
The University of Hong Kong-Shenzhen Hospital
Collaborators
Tianjin Happy Life Technology Co., Ltd.
Responsible party
Sponsor
First posted
Jan 4, 2022
Start date
Dec 30, 2021 (estimated)
Primary completion
Dec 30, 2023 (estimated)
Completion
Mar 30, 2024 (estimated)
Last update
Jan 4, 2022

Study contacts

Zhiyuan Xu, MD
Contact
xuzy@hku-szh.org
+86-18307555170
Yongmei Li, MD
principal investigator · The University of Hong Kong-Shenzhen Hospital
Weitang Wu
principal investigator · The University of Hong Kong-Shenzhen Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

The University of Hong Kong-Shenzhen Hospital

Start the discussion